سعر Kombiglyza xr 5/1000 mg 30 tablets 2022

Kombiglyza XR saxagliptin 5 mg / metformin hydrochloride 1000 mg extended-release tablets, pack of 30 (Bristol-Myers Squibb brand, United Pharma, Egypt); oral combination for type 2 diabetes.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus; not recommended for type 1 diabetes or diabetic ketoacidosis (US label of same-formulation saxagliptin/metformin HCl extended-release tablets).Population: Adults with type 2 diabetes mellitusDailyMed (U.S. National Library of Medicine)

• Diarrhoea and nausea/vomiting were the most common adverse reactions with metformin extended-release (>5% and more than placebo); saxagliptin-associated reactions are listed in the US label (pooled placebo-controlled trials).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (eGFR below 30 mL/min/1.73 m2); acute or chronic metabolic acidosis including diabetic ketoacidosis; history of serious hypersensitivity (anaphylaxis, angioedema, exfoliative skin conditions) to saxagliptin, metformin or any ingredient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: metformin-associated lactic acidosis (including fatal cases); risk factors include renal impairment, carbonic anhydrase inhibitors such as topiramate, age 65 or older, radiological contrast studies, surgery, hypoxic states, excessive alcohol intake, hepatic impairment and mitochondrial disease.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute pancreatitis (discontinue if suspected); heart failure risk with saxagliptin (consider risks in patients with heart-failure risk factors); vitamin B12 deficiency with metformin (measure haematological parameters annually); hypoglycaemia with insulin or insulin secretagogues (consider lower doses); serious hypersensitivity; severe arthralgia; bullous pemphigoid.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4/5 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin, itraconazole, ritonavir)Significantly increase saxagliptin concentrations; limit dose to 2.5 mg/1000 mg once daily.DailyMed (U.S. National Library of Medicine)
• Carbonic anhydrase inhibitors (e.g. topiramate)May increase the risk of lactic acidosis; consider more frequent monitoring.DailyMed (U.S. National Library of Medicine)
• Drugs that reduce metformin clearanceMay increase the risk of lactic acidosis; consider benefits and risks of concomitant use.DailyMed (U.S. National Library of Medicine)

• Limited data with saxagliptin/metformin or saxagliptin are insufficient to determine a drug-associated risk of major birth defects or miscarriage; published metformin studies have not shown a clear association. Poorly controlled diabetes carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on saxagliptin in human milk (present in rat milk); limited studies show metformin is present in human milk. Weigh breastfeeding benefits against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Saxagliptin: Inhibits DPP-4, prolonging active incretin (GLP-1, GIP) levels and glucose-dependent insulin secretion.
• Metformin hydrochloride: Decreases hepatic glucose production and intestinal glucose absorption and improves insulin sensitivity; formula and molecular weight refer to metformin base (PubChem CID 4091).